Compare TCOM & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCOM | RMD |
|---|---|---|
| Founded | 1999 | 1989 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6B | 36.8B |
| IPO Year | N/A | N/A |
| Metric | TCOM | RMD |
|---|---|---|
| Price | $55.27 | $256.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $80.00 | ★ $293.70 |
| AVG Volume (30 Days) | ★ 4.0M | 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 0.54% | ★ 0.94% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.41 | $10.64 |
| Revenue Next Year | $13.95 | $7.38 |
| P/E Ratio | ★ $9.06 | $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.30 | $199.92 |
| 52 Week High | $79.00 | $293.81 |
| Indicator | TCOM | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 33.48 | 49.76 |
| Support Level | $53.30 | $245.65 |
| Resistance Level | $56.64 | $262.17 |
| Average True Range (ATR) | 1.40 | 8.72 |
| MACD | -0.00 | -0.97 |
| Stochastic Oscillator | 22.37 | 35.66 |
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.